Auris Medical (EARS) Trading Up 7.7%

Auris Medical Holding AG (NASDAQ:EARS)’s share price was up 7.7% during trading on Tuesday . The company traded as high as $0.28 and last traded at $0.28. Approximately 502,765 shares traded hands during mid-day trading, an increase of 18% from the average daily volume of 426,989 shares. The stock had previously closed at $0.26.

Separately, ValuEngine raised shares of Auris Medical from a “sell” rating to a “hold” rating in a research note on Wednesday, May 2nd.

The company has a debt-to-equity ratio of -3.12, a current ratio of 1.40 and a quick ratio of 1.40.

Auris Medical (NASDAQ:EARS) last released its earnings results on Tuesday, May 15th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter.

Institutional investors have recently added to or reduced their stakes in the company. Sofinnova Ventures Inc bought a new stake in shares of Auris Medical in the 1st quarter worth about $1,251,000. Sabby Management LLC bought a new stake in shares of Auris Medical in the 1st quarter worth about $549,000. Finally, Bellevue Group AG bought a new stake in shares of Auris Medical in the 2nd quarter worth about $151,000. Hedge funds and other institutional investors own 26.31% of the company’s stock.

Auris Medical Company Profile (NASDAQ:EARS)

Auris Medical Holding AG, a clinical-stage biopharmaceutical company, focuses on the development of novel products for the treatment of inner ear disorders. Its product candidates include AM-101, which is in phase III clinical development for the treatment of acute inner ear tinnitus; and AM-111 that is in phase III clinical development for the treatment of acute inner ear hearing loss.

Further Reading: Analyst Ratings

Receive News & Ratings for Auris Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Auris Medical and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply